AOD 9604 dosage chart

Reconstitution steps

1. 1Draw 2mL of bacteriostatic water into a sterile syringe.
2. 2Inject the water slowly down the inside wall of the 5MG AOD 9604 vial.
3. 3Swirl gently until fully dissolved — do not shake.
4. 4Use a U-100 insulin syringe for accurate dosing.
5. 5Store reconstituted solution refrigerated at 2–8 °C, protected from light.

Spartan Peptides official protocol

All doses are 1x daily.

• Mixing guide: mix 5MG AOD 9604 with 2mL BAC water.
• Concentration after mixing: 2.5 mg/mL.
• Recommended dosage: 250mcg – 500mcg per day.
• Injection frequency: 1x daily (recommended fasted).
• Use an insulin syringe (U-100) for accurate dosing.

Reported research focus

Research purposes only. Premium quality. Built on legacy. Backed by science.

• Supports fat metabolism*
• Supports weight management*
• Enhances recovery*
• Supports overall wellness*

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes (U‑100, 29–31 gauge); dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Each 5 mg vial provides approximately 10 days of dosing at 500 mcg/day or 16–17 days at 300 mcg/day.

How This Works

AOD‑9604 is a modified C‑terminal fragment of human growth hormone that retains the lipolytic (fat‑reducing) domain without the growth‑promoting effects. It binds to adipose tissue and triggers breakdown of stored fat while blocking new fat storage (re‑esterification) in adipocytes. At the molecular level, chronic AOD‑9604 administration upregulates β3‑adrenergic receptors in fat tissue, reversing obesity‑related suppression of these fat‑burning receptors. Unlike full‑length hGH, AOD‑9604 does not meaningfully elevate IGF‑1 levels or worsen glucose tolerance, making its tolerability indistinguishable from placebo in human trials.

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports reductions in fat mass and increases in fat oxidation over time; clinical trials showed modest but statistically significant weight loss (approximately 2.6 kg vs. 0.8 kg placebo over 12 weeks at 1 mg/day).
• Preferential loss of abdominal fat observed, resembling the pattern seen with low‑dose hGH therapy.
• Does not meaningfully raise IGF‑1 and shows a placebo‑like safety profile in human studies; no anti‑AOD9604 antibodies detected.
• Emerging regenerative potential: preclinical studies suggest possible cartilage repair and bone health benefits.
• Generally well tolerated; occasional mild injection‑site reactions (redness/itch) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a hypocaloric, protein‑forward diet tailored to energy needs; AOD‑9604 is best viewed as a supportive aid to fat loss rather than a stand‑alone solution.
• Combine resistance training and aerobic activity to reinforce metabolic adaptations.
• Prioritize sleep and stress management to support adherence and recovery.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

• Clean the vial stopper and skin with alcohol; allow to dry completely.
• Pinch a skinfold; insert the needle at 90° (or 45° if very little subcutaneous fat) into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

AOD 9604 dosage FAQs